Document is current
Any future updates will be listed below
-
Authors
Chirita, Daria
Bronnec, Pauline
Magnotti, Flora
Dalmon, Sarah
Martin, Amandine
Popoff, Michel http://orcid.org/0000-0001-9305-8989
Gerfaud-Valentin, Mathieu
Sève, Pascal
Belot, Alexandre
Contis, Anne
Duquesne, Agnes
Nocturne, Gaetane
Lemelle, Irene
Georgin-Lavialle, Sophie
Boursier, Guilaine
Touitou, Isabelle
Jamilloux, Yvan
Henry, Thomas http://orcid.org/0000-0002-0687-8565
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (SolvingMEFVariants)
EC | Horizon 2020 Framework Programme (779295)
- License Information
-
More Information
Article History
Received: 8 November 2022
Revised: 11 March 2023
Accepted: 15 March 2023
First Online: 25 March 2023
Competing interests
: The authors declare no competing interests.
: The study was approved by the French Comité de Protection des Personnes SUD-EST IV (CPP,#L16–189), Ile de France IV (CPP, #2018/95) and by the French Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé (CCTIRS, #16.864). The authors observed a strict accordance to the Helsinki Declaration guidelines. HD blood was provided by the Etablissement Français du Sang in the framework of the convention #14–1820. Informed consent was obtained from all healthy donors and patients. All FMF patients fulfilled the Tel Hashomer criteria for FMF. The potential carriage of <i>MEFV</i> mutations in HD was not assessed. Blood samples from HD were drawn on the same day as patients. The number of patients in each experiment is reported in the corresponding figure panels.
